15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Phathom Pharmaceuticals Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $18.00 to $26.00, a moderate spread. The average target of $23.00 sits 92% above the current $11.96. The rating mix has stayed broadly stable, with Buy-side ratings easing from 5 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.05 next quarter toward $1.43 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Phathom Pharmaceuticals Inc.
As of Jul, 3 of 3 firms rate PHAT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PHAT EPS & revenue forecast
EPS · NEXT QUARTER
$0.05
Range $0.02 – $0.11 · 4 analysts · -133% YoY
Next period, 4 analysts expect Phathom Pharmaceuticals Inc to earn $0.05 a share (range $0.02 – $0.11), versus $-0.15 a year earlier. Full-year consensus is $-0.04, growing to $1.43 the year after.
REVENUE · NEXT QUARTER
$92.1M
Range $90.0M – $95.5M · 4 analysts · +86% YoY
Revenue is expected to reach $92.1M (range $90.0M – $95.5M), +86.1% year-over-year. Full-year consensus is $333.8M, rising to $540.0M next year.
Top analysts covering Phathom Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PHAT.
#1
Chase Knickerbocker
Craig-Hallum · Rank #25
Buy
No targeton PHAT
Overall win rate
58%
+ Follow
#2
Yatin Suneja
Guggenheim · Rank #28
Buy
$25.00+109.0% to target
Overall win rate
52%
+ Follow
#3
MC
Matthew Caufield
HC Wainwright & Co. · Rank #51
Buy
$26.00+117.4% to target
Overall win rate
56%
+ Follow
#4
Kristen Kluska
Cantor Fitzgerald · Rank #162
Buy
$29.00+142.5% to target
Overall win rate
38%
+ Follow
#5
Joseph Stringer
Needham · Rank #168
Buy
$28.00+134.1% to target
Overall win rate
36%
+ Follow
PHAT stock forecast FAQ
What is PHAT's average 12-month price target?+
The 3 analysts with a live target average $23.00 for Phathom Pharmaceuticals Inc over the next 12 months, ranging from a $26.00 high to a $18.00 low.
Is PHAT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PHAT?+
The Street-high target is $26.00 (HC Wainwright & Co.), and the Street-low is $18.00 (Barclays). The average of all 3 active targets is $23.00.
How many Wall Street analysts cover PHAT?+
3 analysts have an active rating on Phathom Pharmaceuticals Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering PHAT?+
Among analysts who currently cover PHAT, Chase Knickerbocker of Craig-Hallum has the strongest overall Quantellect track record (Rank #25). Their current call is Buy.
What is Phathom Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.05 per share (range $0.02 – $0.11) across 4 analysts. Full-year EPS is projected at $-0.04, rising to $1.43 the following year.
How much revenue is Phathom Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $92.1M (range $90.0M – $95.5M). Full-year revenue is projected at $333.8M, growing to $540.0M next year.
Have analysts been upgrading or downgrading PHAT lately?+
As of Jul, 3 of 3 firms rate PHAT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PHAT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
